Focal therapy for localized prostate cancer in highly selected patients is feasible and has acceptable morbidity, a French study found.
In a study of 106 patients who underwent focal therapy for low-risk unilateral disease, Eric Barret, MD, and collaborators at the Université Paris Descartes in Paris observed a less than 2% rate of major complications, according to findings published online in European Urology.
Of the 106 patients, 50 (47%) had cryotherapy, 23 (22%) had vascular-targeted photodynamic therapy, and 21 (20%) had high-intensity focused ultrasound. The patients had a median PSA level of 6.1 ng/mL and all had a Gleason score of 6. The median prostate weight was 43 grams.
Preoperatively, the study population had a median International Prostate Symptom Score of 6 and a median International Index of Erectile Function score of 20.
After treatment, the median PSA leves was 3.1, 2.9, and 2.7 ng/mL at three, six, and 12 months, respectively. Treatment-related complications occurred in 13% of patients. The researchers observed 11 minor complicatinos (10 grade 1 and one grade 2), two grade 3 complications, and no grade 4 or higher complications.